SAN DIEGO--(BUSINESS WIRE)--Tentarix Biotherapeutics, a biotechnology company focused on leveraging its proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics, today announced it has raised $35 million in a Series B financing led by Amplitude Ventures with participation from Gilead Sciences, Inc., and founding investors Versant Ventures and Samsara BioCapital..

圣地亚哥--Tentarix Biotherapeutics，一家专注于利用其专有触手的生物技术公司™ 发现和开发多功能，有条件的蛋白质疗法的平台今天宣布，在由Gilead Sciences，Inc.参与的Amplity Ventures以及创始投资者Versant Ventures和Samsara BioCapital领导的B系列融资中，它已筹集3500万美元。。

“With the support of this group of industry-leading investors, we are well-capitalized to continue advancing our promising Tentacles™ platform,” said President and CEO Paul Grayson. “This financing, combined with our recently announced collaboration with Gilead, extends our cash runway and enables us to expand our pipeline of cell-specific, conditionally active multifunctional biologics that have the potential to tackle previously undruggable targets.”.

“在这一群行业领先的投资者的支持下，我们有足够的能力继续推进我们有希望的触手™ 平台，”总裁兼首席执行官Paul Grayson说。“这项融资与我们最近宣布的与Gilead的合作相结合，扩展了我们的cash跑道，使我们能够扩展我们的细胞特异性，有条件活性的多功能生物制剂管道，这些生物制剂有可能解决以前无法实现的目标。”。

“Amplitude believes that multifunctional biologics enable more powerful therapeutic approaches, and we are convinced that Tentarix’s unique technology platform leads the industry,' said Amplitude’s Allyson Tighe, who joined Tentarix’s board in connection with the Series B financing. 'We’re excited to be working with this exceptional management team and investor syndicate to further advance this work and to enable meaningful therapies for patients.”.

“Amplitude认为多功能生物制剂能够提供更强大的治疗方法，我们相信Tentarix独特的技术平台引领了该行业，”Amplitude的Allyson Tighe说，他加入了Tentarix的董事会，参与了B系列融资。我们很高兴能与这个卓越的管理团队和投资者集团合作，进一步推进adva完成这项工作并为患者提供有意义的治疗方法。”。

Since inception, Tentarix has now brought in $132 million in capital from equity and upfront partnership payments.

自成立以来，Tentarix现已通过股权和前期合作支付带来1.32亿美元的资本。

About Tentarix

关于Tentarix

Tentarix’s mission is to develop first-in-class targeted, multifunctional, conditional therapies. The Company is focused on modalities that have cell-specific function and has built a team that aims to transform biologics. For more information, please visit www.tentarix.com.

Tentarix的使命是开发一流的靶向，多功能，有条件的疗法。该公司专注于具有细胞特异性功能的模式，并建立了一个旨在改变生物制剂的团队。欲了解更多信息，请访问www.tentarix.com。

About Amplitude

关于振幅

Amplitude is a full-stack venture capital firm employing a unique growth model to build companies with novel science, world-class management teams, and big visions and to scale those companies to breakout potential. With over $ 500M under management and offices in Montreal, Toronto and Vancouver, Amplitude applies a proven, evidence-based approach to investing in leading precision medicine companies.

Amplitude是一家完整的风险投资公司，采用独特的增长模式，建立具有新颖科学，一流管理团队和大愿景的公司，并扩大这些公司的潜力。AMPITURE在蒙特利尔，多伦多和温哥华的管理和办事处下拥有超过5亿美元，采用经过验证的循证方法投资领先的精准医药公司。

Please visit amplitudevc.com..

请访问amplitudevc.com。。

About Versant Ventures

关于Versant Ventures

Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $5.4 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and R&D expertise that enables a hands-on approach to company building.

Versant Ventures是一家领先的医疗保健风险投资公司，致力于帮助杰出的企业家建立下一代大公司。该公司的重点是发现和开发新疗法的生物技术公司。Versant在美国，加拿大和欧洲的管理和办事处下拥有54亿美元，建立了一支拥有深度投资，运营和研发专业知识的团队，可以为公司建设提供实践方法。

Since the firm’s founding in 1999, more than 95 Versant companies have achieved successful acquisitions or IPOs. For more information, please visit www.versantventures.com..

自1999年该公司成立以来，已有95多家Versant公司成功收购或首次公开发行。欲了解更多信息，请访问www.versantventures.com。。

About Samsara BioCapital

关于Samsara BioCapital

Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Founded in 2016 by Srinivas Akkaraju, M.D., Ph.D., our team of scientists, investors and entrepreneurs takes a long-term view to value creation across all stages of public and private life science companies.

Samsara BioCapital是一种新型生物技术投资基金，专注于将尖端生物学转化为新疗法，以治疗未满足医疗需求的患者。我们的科学家，投资者和企业家团队于2016年由Srinivas Akkaraju博士创建，长期致力于公共和私人生命科学公司各个阶段的价值创造。

We believe in a collaborative, hands-on approach, working closely with entrepreneurs to harness exciting scientific advances and build leading companies. Samsara actively manages assets on behalf of endowments, foundations and family offices. For more information, please visit www.samsaracap.com..

我们相信采用协作，动手的方式，与企业家密切合作，利用令人兴奋的科学进步，建立领先的公司。Samsara代表捐赠，基金会和家庭办公室积极管理资产。欲了解更多信息，请访问www.samsaracap.com。。